Equillium, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report; the filing text does not provide standalone fourth-quarter financial results.
Business context
Equillium is a clinical-stage biotechnology company with no product revenue. Its lead candidate, itolizumab (EQ001), targets CD6 and was being developed for acute graft-versus-host disease (aGVHD) and lupus/lupus nephritis. In Q4 2021, the company completed a Phase 1b uncontrolled-asthma study, meeting its primary safety and tolerability objective, but deprioritized further asthma development amid pandemic-related trial challenges.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | No revenue | No revenue |
| Research and development expense | $26.4 million | $19.4 million |
| General and administrative expense | $11.4 million | $10.2 million |
| Total operating expenses | $37.8 million | $29.5 million |
| Net loss | $39.1 million | $29.8 million |
| Net loss per share, basic and diluted | $1.36 | $1.46 |
| Net cash used in operating activities | $32.1 million | $24.6 million |
- At December 31, 2021, cash and cash equivalents were $50.4 million and short-term investments were $30.3 million, totaling $80.7 million. Management expected these resources to fund planned operations for at least 12 months from the filing date, but noted estimates and plans could change.
- Total assets were $85.4 million; total liabilities were $18.9 million; stockholders’ equity was $66.5 million. Current assets were $83.4 million versus current liabilities of $8.9 million.
- Notes payable had a $10.2 million carrying amount, including $1.4 million current and $8.8 million long-term. The $10.0 million term loan bears interest at the greater of 8.25% or prime plus 3.00%, matures June 1, 2024, and is secured by substantially all assets other than most intellectual property. Interest-only payments were extended through September 30, 2022 following a March 2022 lender confirmation.
- No meaningful operating margins are available because the company had no revenue. The filing reports no off-balance-sheet arrangements; contingent milestone obligations are discussed below.
Material changes and developments
- Compared with 2020, R&D expense rose $7.0 million, primarily from higher staffing and clinical-trial costs, including EQUATOR start-up expenses. G&A rose $1.2 million, mainly due to increased employee costs.
- Net loss widened by $9.2 million, while operating cash use increased $7.5 million. Cash and cash equivalents increased by $26.4 million, reflecting $31.1 million of financing cash flow and $27.4 million of investing cash flow, partly offset by operating cash use.
- In February 2021, a registered direct offering generated $29.9 million net proceeds and included warrants to purchase 1.29 million shares at an initial $14.00 exercise price. Common shares outstanding at year-end were 29.46 million.
- After year-end, on February 14, 2022, Equillium acquired Bioniz Therapeutics, adding EQ101, EQ102 and a peptide-discovery platform. Consideration included up to 5.70 million shares and contingent payments of up to $57.5 million for regulatory events and $250 million for commercialization events relating to EQ101.
Outlook, commentary and key risks
- In March 2022, Equillium initiated EQUATOR, a pivotal Phase 3 study of itolizumab with corticosteroids as first-line treatment for aGVHD. The filing reports prior Phase 1b data: among 18 patients treated within three days of first steroid administration, Day 29 complete response was 61%; the broader study data were preliminary and remain subject to verification and change.
- The company planned to report interim data from the lupus-nephritis Type B EQUALISE study in mid-2022. It expected to initiate a Phase 2 EQ101 study in alopecia areata and a Phase 1 EQ102 study in celiac disease in the second half of 2022; these were plans, not completed milestones as of the filing.
- Equillium expects substantial future losses and negative cash flows and will need additional financing to complete development and potential commercialization. Additional capital may dilute shareholders, restrict operations or require licensing rights. It had no approved products and had never generated revenue.
- Itolizumab is licensed from Biocon for the United States, Canada, Australia and New Zealand. The agreement carries development diligence obligations, up to $30 million in regulatory milestones, up to $565 million in sales milestones and tiered royalties. Biocon is also the exclusive supplier and manufacturer, creating supply and execution dependency.
- The company relies on an OFAC general license for Cuban-origin pharmaceuticals to conduct itolizumab clinical trials; a change or loss of authorization could disrupt the program. Other material risks include clinical-trial delay or failure, safety findings, COVID-19 effects, competition, intellectual-property challenges, and the lack of commercial infrastructure.
- Management reported effective disclosure controls and internal control over financial reporting as of year-end. KPMG audited the financial statements and issued an unqualified opinion; it was not engaged to audit internal control effectiveness. The filing reported no litigation as of December 31, 2021.
Important facts for investors to verify
- Whether the cash runway remains adequate after the Bioniz acquisition, expanded pipeline spending and launch of the Phase 3 aGVHD trial.
- Enrollment, safety, efficacy and regulatory milestones for EQUATOR and EQUALISE, including whether preliminary clinical findings are confirmed in later-stage data.
- Actual timing and financing requirements for the planned EQ101 and EQ102 studies, and the terms and potential dilution from Bioniz share and milestone consideration.
- Biocon’s manufacturing capacity and continued supply, Equillium’s license diligence status, and any developments affecting the OFAC authorization.
- Debt covenant compliance, repayment schedule and access to additional financing, including the effect of equity issuance and outstanding warrants.